Original Article

You have full text access to this OnlineOpen article

Unexpected long-term survival after low-dose palliative radiotherapy for nonsmall cell lung cancer

  1. Michael P. Mac Manus M.D.1,†,*,
  2. Jane P. Matthews Ph.D.2,
  3. Morikatsu Wada4,
  4. Andrew Wirth1,
  5. Valentina Worotniuk3,
  6. David L. Ball M.D.1

Article first published online: 23 JAN 2006

DOI: 10.1002/cncr.21704

Issue

Cancer

Cancer

Volume 106, Issue 5, pages 1110–1116, 1 March 2006

Additional Information

How to Cite

Mac Manus, M. P., Matthews, J. P., Wada, M., Wirth, A., Worotniuk, V. and Ball, D. L. (2006), Unexpected long-term survival after low-dose palliative radiotherapy for nonsmall cell lung cancer. Cancer, 106: 1110–1116. doi: 10.1002/cncr.21704

Author Information

  1. 1

    Department of Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

  2. 2

    Center for Biostatistics and Clinical Trials, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

  3. 3

    Patient Record Information Department, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

  4. 4

    Department of Radiation Oncology, Austin and Repatriation Medical Center, Melbourne, Victoria, Australia

  1. †

    Fax: (011) 613-9656-1424

*Consultant Radiation Oncologist, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Victoria 3000, Australia

Publication History

  1. Issue published online: 17 FEB 2006
  2. Article first published online: 23 JAN 2006
  3. Manuscript Accepted: 29 SEP 2005
  4. Manuscript Revised: 31 AUG 2005
  5. Manuscript Received: 31 MAY 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (107K)

REFERENCES

  • 1
    Penland SK, Socinski MA. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol. 2004; 14: 326–334.
  • 2
    Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer. 1997; 21: 129–183.
  • 3
    Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin Oncol. 1999; 17: 3188–3194.
  • 4
    Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol. 1999; 26(1 Suppl 4 ): 3–11.
  • 5
    Macbeth FR, Bolger JJ, Hopwood P, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996; 8: 167–175.
  • 6
    Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multiinstitutional trial. Int J Radiat Oncol Biol Phys. 1985; 11: 751–758.
  • 7
    Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer. 1998; 34: 1036–1044.
  • 8
    Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995; 13: 1221–1230.
  • 9
    Ball D, Matthews J, Worotnouk V, Crennan E. Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993; 25: 599–604.
  • 10
    Fowler JR. Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol. 1992; 2: 16–21.
  • 11
    Mac Manus MP, Wada M, Matthews J, Ball DL. Characteristics of 47 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. Int J Radiat Oncol Biol Phys. 2000; 46: 63–69.
  • 12
    Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 1711–1717.
  • 13
    Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343–346.
  • 14
    Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457–480.
  • 15
    Quddus AM, Kerr GR, Price A, Gregor A. Long-term survival in patients with non-small cell lung cancer treated with palliative radiotherapy. Clin Oncol. 2001; 13: 95–98.
  • 16
    Satoh H, Ishikawa H, Naito T, et al. Analysis of long-term survivors after platinum containing chemotherapy in non-small cell lung cancer. Anticancer Res. 1998; 18: 1295–1298.
  • 17
    Sculier JP, Paesmans M, Libert P, et al. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working party. Eur J Cancer. 1994; 30A: 1342–1347.
  • 18
    Saitoh Y, Fujisawa T, Shiba M, et al. Prognostic factors in surgical treatment of solitary brain metastasis after resection of non-small-cell lung cancer. Lung Cancer. 1999; 24: 99–106.
  • 19
    Leo F, Nicholson AG, Hansell DM, Corrin B, Pastorino U. Spontaneous regression of large-cell carcinoma of the lung: a rare observation in clinical practice. Thorac Cardiovasc Surg. 1999; 47: 53–55.
  • 20
    Kappauf H, Gallmeier WM, Wunsch PH, et al. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved. Ann Oncol. 1997; 8: 1031–1039. Review.
  • 21
    Schofield P, Ball D, Smith JG, et al. Optimism and survival in lung carcinoma patients. Cancer. 2004; 100: 1276–1282.
    Direct Link:
  • 22
    Peters LJ. The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol. 1990; 17: 177–190.
  • 23
    Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest. 1996; 109: 271–276.
  • 24
    Luketich JD, Burt ME. Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg. 1996; 62: 1614–1616.
  • 25
    Porte HL, Roumilhac D, Graziana JP. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg. 1998; 65: 331–335.
  • 26
    Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat–cell carcinoma of the lung. Cancer. 1980; 45: 2744–2753.
    Direct Link:
  • 27
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899–909.
  • 28
    Saunders MI, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet. 1997; 350: 161–165.
View Full Article (HTML) Get PDF (107K)